NDA 214628/S-004

SUPPLEMENT APPROVAL

Long Grove Pharmaceuticals, LLC (A Capstone Development Services Company)
Attention: Parthrajsinh Jadeja
Sr. Manager, Regulatory Affairs
9450 W. Bryn Mawr Ave.
Suite 200
Rosemont, IL 60018

Dear Parthrajsinh Jadeja:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 7, 2024, and your amendments, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Norepinephrine in Sodium Chloride injection.

We also refer to our approval letter dated December 3, 2024, which contained the following error: yellow highlights over the overwrap labels and blue highlights on the carton labels.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain December 3, 2024, the date of the original approval letter.

This Prior Approval supplemental new drug application provides for extension of the out of the aluminum pouch stability of the drug product from 7 days to 45 days.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

We acknowledge your November 19, 2024, submission containing final printed carton and container labeling.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Musse Olani, Pharm.D., Regulatory Business Process Manager, at musse.olani@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Gurpreet Gill-Sangha, Ph.D.
Supervisor
Division of Product Quality Assessment II
Office of Product Quality Assessment I
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling
Carton and Container Labeling

Gurpreet
Gill Sangha

Digitally signed by Gurpreet Gill Sangha
Date: 12/05/2024 04:18:44PM
GUID: 5135f2ad000117842392c50c36c7f28a